EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer

By sjmartinez • April 28, 2024

Chan AM, Aguirre B, Liu L, Mah V, Balko JM, Tsui J, Wadehra NP, Moatamed NA, Khoshchehreh M, Dillard CM, Kiyohara M, Elshimali Y, Chang HR, Marquez-Garban D, Hamilton N, Pietras RJ, Gordon LK, Wadehra M. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancers (Basel). 2024 Apr 12;16(8):1481. doi: 10.3390/cancers16081481. PMID: 38672563; PMCID: PMC11048488.

Tags: Biomarker, chemotherapy, epithelial membrane protein 2, Hematology/Oncology, King Drew Med Ctr, Publications, triple-negative breast cancer

Related Posts

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells

Dimapasoc M, Moran JA, Cole SW, Ranjan A, Hourani R, Kim JT, Wender PA, Marsden MD, Zack JA. Defining the Effects of PKC Modulator HIV[...]

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

Liu JF, Gaillard S, Wahner Hendrickson AE, Yeku O, Diver E, Gunderson Jackson C, Arend R, Ratner E, Samnotra V, Gupta D, Chung J, Zhang[...]

Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update

Bower JE, Lacchetti C, Alici Y, Barton DL, Bruner D, Canin BE, Escalante CP, Ganz PA, Garland SN, Gupta S, Jim H, Ligibel JA, Loh[...]